TOKYO, Nov 27, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Electric Building Solutions Corporation (MEBS, Head Office: Chiyoda-Ku, Tokyo; President: Iwao Oda) today announced that Mitsubishi Electric de Mexico S.A. de C.V. (MELMEX), which is responsible for elevator and escalator sales in Mexico, completed the renewal of one of the spiral escalators at the Liverpool department store in the Centro Santa Fe shopping mall in Santa Fe, Mexico on October 15. This project was the first-ever spiral escalator renewal project conducted anywhere in the world.Spiral escalator after the renewalSpiral escalators, which are curved escalators that trace an arc, are manufactured exclusively by MEBS. The unit that was renewed this time is one of two spiral escalators in Mexico delivered by the company in 1992 that remain in operation today. Elevators and escalators undergo continuous and appropriate maintenance in order to sustain and restore their functionality. However, the risks associated with deterioration through aging and the number of discontinued or unavailable parts increase over time. Through this renewal, the company replaced key components at an optimal timing, enhancing the e...

TOKYO and CAMBRIDGE, Mass., Nov. 26, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: HaruoNaito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has completed the rolling submission of the Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector(SC-AI), LEQEMBI IQLIK, as a weekly starting dose after the FDA granted Fast Track Status. LEQEMBI is indicated for the treatment of Alzheimer’s disease (AD) in patients with Mild Cognitive Impairment(MCI) or mild dementia stage of disease (collectively referred to as early AD). Upon acceptance of the sBLA, the FDA will set a Prescription Drug User Fee Act (PDUFA) action date (target date for review completion). The sBLA is supported by data evaluating subcutaneous (SC) administration of lecanemab across arange of doses and as part of sub-studies within the Phase 3 Clarity AD open-label extension (OLE)following the 18-month core study in individua...

KAWASAKI, Japan, Nov 26, 2025 - (JCN Newswire via SeaPRwire.com) - Fujitsu today announced the development of a technology for rapidly and accurately quantifying blue carbon, i.e., carbon absorbed and stored by marine and coastal ecosystems, from seaweed and seagrass, supporting the restoration and conservation of seagrass beds. This innovation, part of Fujitsu's research and development into ocean digital twin technology, significantly accelerates the certification process for blue carbon credits, a key initiative in decarbonization and marine environmental preservation.The newly developed technology enables data collection, measurement, ecosystem recognition, blue carbon quantification, and support for recovery and conservation activities without requiring specialized experts. The system has been validated to measure and recognize with over 85% accuracy and quantify blue carbon in areas exceeding 1 hectare, in 1/100th of the time previously required (i.e., approximately 30 minutes per hectare).The technology's effectiveness was confirmed through the attainment of J-Blue Credit® [1] certification, receiving a distinguished 95% accreditation rate.Moving forward, Fujitsu wi...

KAWASAKI, Japan, Nov 26, 2025 - (JCN Newswire via SeaPRwire.com) - Fujitsu today announced that it has won both the AI Innovation and the Migrate SAP awards at the 2025 Microsoft Japan Partner of the Year presented by Microsoft Japan Co., Ltd. This recognition acknowledges Fujitsu's contributions in leveraging Microsoft products to support customer business transformation in Japan through AI and RISE with SAP. This marks the first time Fujitsu has received an award in the AI field from Microsoft.The Microsoft Japan Partner of the Year Awards recognizes those partners of Microsoft Japan that have gained the trust of their customers by achieving exceptional results during the past year. These latest accolades mark the 7th consecutive year that Fujitsu has been recognized by Microsoft Japan in these awards.Fujitsu received the AI Innovation Award for its collaboration with Headwaters Co., Ltd., to develop a prototype generative AI solution for Japan Airlines Co., Ltd. This solution enables cabin crew to create reports in a chat format using tablet devices during flights, leveraging Microsoft's AI development tool Azure AI Foundry and Headwaters' small language model (SLM) Phi. Th...